First-pass extracted concept

drug-inducible and transient expression CAR systems

Candidate: concept label1 source documents3 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

These systems provide controllable CAR expression or activity so CAR cells can be modulated over time.

Source 1DOI PubMed

Resources required

The abstract indicates that inducible or transient expression control features are required, but does not specify the exact drugs or constructs.

Source 1DOI PubMed

What problem it solves

They are presented as a way to reduce toxicity by allowing controlled modulation of CAR cells.

Source 1DOI PubMed

What it does not solve

The abstract does not establish that these systems solve AML target specificity on their own.

Source 1DOI PubMed

Alternatives

Nearby alternatives in the abstract include logic-gated CARs, pharmacologic or suicide switches, adapter CAR platforms, and alternative effector-cell platforms.

Source 1DOI PubMed

Evidence Snippets

Drug-inducible and transient expression systems, as well as pharmacologic or suicide switches, enable controlled modulation or elimination of CAR cells to reduce toxicity.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1capabilitysupports2025Source 1DOI PubMed

Drug-inducible and transient expression systems and pharmacologic or suicide switches enable controlled modulation or elimination of CAR cells to reduce toxicity.

Quoted textsource-backed

Drug-inducible and transient expression systems, as well as pharmacologic or suicide switches, enable controlled modulation or elimination of CAR cells to reduce toxicity.

Claim 2limitationsupports2025Source 1DOI PubMed

CAR T-cell therapy in AML has been limited by early relapses and severe toxicities.

Quoted textsource-backed

its application in AML has been limited by early relapses and severe toxicities

Claim 3mechanism or rationalesupports2025Source 1DOI PubMed

Most AML-associated surface antigens are also expressed on healthy hematopoietic stem and progenitor cells, creating risks of on-target/off-tumor toxicity and prolonged myeloablation.

Quoted textsource-backed

most AML-associated surface antigens are also expressed on healthy hematopoietic stem and progenitor cells, creating significant risks of on-target/off-tumor toxicity and prolonged myeloablation